Pacira BioSciences (PCRX) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

PCRX Pacira BioSciences

Watchlist

18.580
-0.100-0.54%

Close Jan 8 16:00 ET

18.580
0.0000.00%

Post 16:20 ET

857.90MMarket Cap-9.38P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
Zacks Jan 8 10:35 ET
Pacira BioSciences Secures FDA Approval For New Iovera SmartTip to Manage Chronic Low Back Pain
BenzingaJan 7 11:49 ET
Express News | Pacira Biosciences Receives FDA 510K Clearance for New Iovera° Smarttip to Manage Chronic Low Back Pain via Long-Lasting Medial Branch Nerve Block
ReutersJan 7 08:00 ET
RBC Raises Price Target on Pacira Biosciences to $18 From $16, Keeps Sector Perform Rating
MT NewswiresJan 7 07:49 ET · Ratings
Insider Sale: Chief Medical Officer of $PCRX (PCRX) Sells 879 Shares
Quiver QuantitativeJan 6 18:31 ET
Pacira BioSciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Pacira BioSciencesJan 2 00:00 ET

Comments

Value investorr

Aug 23, 2024 11:25

My last point: looking into the future of PCRX.

$Pacira BioSciences (PCRX.US)$ $iShares Russell 2000 ETF (IWM.US)$
Besides all the information that is publicly available and that I’ve posted in my previous two comments. Here’s something to keep in mind for PCRX future if you want to make your decision to buy, hold, or sell:
1. Diversification of product pipeline greatly reduces the risk of further top-line (revenue) erosion even if we assume the worst case scenario for Experal (which itself is ex...

Value investorr

Aug 19, 2024 10:03

A undervalued keeper

$Pacira BioSciences (PCRX.US)$ I believe whoever saw my last comment om this stock has generated a good return over the past week. I think the opportunity is still not fully capitalized and fundamental reasonings from last time still persist.
Additionally, just look at the imsider activities. Wow, from CEO to multiple directors, they are buying and loading a ton of shares and no one is selling. This is just another signal supports my theory and the share price. From its funda...

Share Your Profit/Loss

Mr Long Term

Aug 13, 2024 17:42

Columns Top Calls on Wall Street: Starbucks, Dell, Warner Bros. and More.

Top 5 Upgrades:
Baird upgraded Starbucks $Starbucks (SBUX.US)$ to Outperform from Neutral with a price target of $110, up from $81. The firm sees a more favorable risk/reward on Starbucks shares following the hiring of Brian Niccol as CEO.
Barclays upgraded Dell Technologies $Dell Technologies (DELL.US)$ to Equal Weight from Underweight with an unchanged price target of $97. The firm says much of the artificial intelligence "hype" ...

Value investorr

Aug 12, 2024 09:29

A golden opportunity

$Pacira BioSciences (PCRX.US)$ Let’s layout their current situation and see if the market has priced it appropriately:
Good news:
1. ASP for Exparel +6% reimbursement from the new law
2. THREE Extra upcoming Patent litigation against eVenus infringement
3. Despite the approval, Truist Securities anticipates that eVenus will not be able to launch its generic product until at least the late 2030s due to ongoing patent litigations which means LIMITED DOWNSIDE to current revenue...